Magnus Bein1,2, Oriana Hoi Yun Yu3,4, Sonia Marzia Grandi5, Francesca Y E Frati6, Ihab Kandil2, Kristian B Filion7,8,9. 1. Department of Biology, McGill University, Montreal, Quebec, Canada. 2. Department of Medicine, McGill University, Montreal, Quebec, Canada. 3. Division of Endocrinology, Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada. 4. Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada. 5. Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA. 6. Department of McGill University Library & Archives, McGill University, Montreal, Quebec, Canada. 7. Department of Medicine, McGill University, Montreal, Quebec, Canada. kristian.filion@mcgill.ca. 8. Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada. kristian.filion@mcgill.ca. 9. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada. kristian.filion@mcgill.ca.
Abstract
BACKGROUND: Levothyroxine replacement therapy may decrease the risk of adverse pregnancy outcomes among women with subclinical hypothyroidism (SCH). The aim of this study is to conduct a systematic review and meta-analysis to examine the risk of adverse pregnancy, perinatal, and early childhood outcomes among women with SCH treated with levothyroxine. METHODS: A systematic literature search was conducted using Ovid-Medline, Ovid-EMBASE, Pubmed (non-Medline), Ebsco-CINAHL Plus with full text and Cochrane Library databases. Randomized controlled studies (RCTs) and observational studies examining the association between treatment of SCH during pregnancy and our outcomes of interest were included. Studies that compared levothyroxine treatment versus no treatment were eligible for inclusion. Data from included studies were extracted and quality assessment was performed by two independent reviewers. RESULTS: Seven RCTs and six observational studies met our inclusion criteria. A total of 7342 individuals were included in these studies. RCTs demonstrated several sources of bias, with lack of blinding of the participants or research personnel; only one study was fully blinded. In the observational studies, there was moderate to serious risk of bias due to lack of adjustment for certain confounding variables, participant selection, and selective reporting of results. Pooled analyses showed decreased risk of pregnancy loss (RR: 0.79; 95% CI: 0.67 to 0.93) and neonatal death (RR: 0.35; 95% CI: 0.17 to 0.72) associated with levothyroxine treatment during pregnancy among women with SCH. There were no associations between levothyroxine treatment and outcomes during labour and delivery, or cognitive status in children at 3 or 5 years of age. CONCLUSION: Treatment of SCH with levothyroxine during pregnancy is associated with decreased risks of pregnancy loss and neonatal death. Given the paucity of available data and heterogeneity of included studies, additional studies are needed to address the benefits of levothyroxine use among pregnant women with SCH.
BACKGROUND:Levothyroxine replacement therapy may decrease the risk of adverse pregnancy outcomes among women with subclinical hypothyroidism (SCH). The aim of this study is to conduct a systematic review and meta-analysis to examine the risk of adverse pregnancy, perinatal, and early childhood outcomes among women with SCH treated with levothyroxine. METHODS: A systematic literature search was conducted using Ovid-Medline, Ovid-EMBASE, Pubmed (non-Medline), Ebsco-CINAHL Plus with full text and Cochrane Library databases. Randomized controlled studies (RCTs) and observational studies examining the association between treatment of SCH during pregnancy and our outcomes of interest were included. Studies that compared levothyroxine treatment versus no treatment were eligible for inclusion. Data from included studies were extracted and quality assessment was performed by two independent reviewers. RESULTS: Seven RCTs and six observational studies met our inclusion criteria. A total of 7342 individuals were included in these studies. RCTs demonstrated several sources of bias, with lack of blinding of the participants or research personnel; only one study was fully blinded. In the observational studies, there was moderate to serious risk of bias due to lack of adjustment for certain confounding variables, participant selection, and selective reporting of results. Pooled analyses showed decreased risk of pregnancy loss (RR: 0.79; 95% CI: 0.67 to 0.93) and neonatal death (RR: 0.35; 95% CI: 0.17 to 0.72) associated with levothyroxine treatment during pregnancy among women with SCH. There were no associations between levothyroxine treatment and outcomes during labour and delivery, or cognitive status in children at 3 or 5 years of age. CONCLUSION: Treatment of SCH with levothyroxine during pregnancy is associated with decreased risks of pregnancy loss and neonatal death. Given the paucity of available data and heterogeneity of included studies, additional studies are needed to address the benefits of levothyroxine use among pregnant women with SCH.
Authors: Emmy van den Boogaard; Rosa Vissenberg; Jolande A Land; Madelon van Wely; Joris A M van der Post; Mariette Goddijn; Peter H Bisschop Journal: Hum Reprod Update Date: 2011-05-28 Impact factor: 15.610
Authors: Brian M Casey; Jodi S Dashe; C Edward Wells; Donald D McIntire; William Byrd; Kenneth J Leveno; F Gary Cunningham Journal: Obstet Gynecol Date: 2005-02 Impact factor: 7.661
Authors: Erik K Alexander; Elizabeth N Pearce; Gregory A Brent; Rosalind S Brown; Herbert Chen; Chrysoula Dosiou; William A Grobman; Peter Laurberg; John H Lazarus; Susan J Mandel; Robin P Peeters; Scott Sullivan Journal: Thyroid Date: 2017-03 Impact factor: 6.568
Authors: Spyridoula Maraka; Naykky M Singh Ospina; Derek T O'Keeffe; Ana E Espinosa De Ycaza; Michael R Gionfriddo; Patricia J Erwin; Charles C Coddington; Marius N Stan; M Hassan Murad; Victor M Montori Journal: Thyroid Date: 2016-03-03 Impact factor: 6.568